Cargando…

Significant benefit of nivolumab combining radiotherapy in metastatic gallbladder cancer patient with strong PD-L1 expression: a case report

BACKGROUND: Gallbladder cancer (GBC) is the main pathological type of biliary tract cancers. Due to its aggressive nature, GBC is usually diagnosed at advanced stages with limited therapeutic options and poor outcome, especially after failure of chemotherapy. CASE PRESENTATION: Herein, we report a r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Weiwei, Wei, Jia, Liu, Juan, Qiu, Yudong, Shi, Jiong, He, Jian, Su, Mu, Xiao, Mingzhe, Liu, Baorui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625641/ https://www.ncbi.nlm.nih.gov/pubmed/31360065 http://dx.doi.org/10.2147/OTT.S208926

Ejemplares similares

Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review
por: Zhang, Zhe, et al.
Publicado: (2017)

Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report
por: Tang, Xiao, et al.
Publicado: (2020)

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
por: Paoluzzi, L., et al.
Publicado: (2016)

Effective treatment of gallbladder neuroendocrine carcinoma with nivolumab
por: Kanda, Shinichiro, et al.
Publicado: (2023)

Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review
por: Su, Xiangyu, et al.
Publicado: (2020)

Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma
por: Yu, Jeong Il, et al.
Publicado: (2019)

Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma
por: Teishima, Jun, et al.
Publicado: (2023)

Concurrent use of nivolumab and radiotherapy for patients with metastatic non-small cell lung cancer and renal cell carcinoma with oligometastatic disease progression on nivolumab
por: Ansari, Jawaher, et al.
Publicado: (2021)

Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma
por: Lin, Jing, et al.
Publicado: (2022)

Nivolumab in combination with radiotherapy for metastatic esophageal neuroendocrine carcinoma after esophagectomy: a case report
por: Takagi, Kuniyasu, et al.
Publicado: (2021)

Successful Treatment of Metastatic Gallbladder Carcinoma with PD-L1 Expression by the Combination of PD-1 Inhibitor Plus Bevacizumab with Chemotherapy: A Case Report
por: Guo, Lihong, et al.
Publicado: (2022)

Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers
por: Kong, Yuehong, et al.
Publicado: (2021)

Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report
por: Mizutani, Kosuke, et al.
Publicado: (2017)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Stereotaktische Radiotherapie plus Nivolumab bei NSCLC
por: Krug, David, et al.
Publicado: (2023)

Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report
por: Paraghamian, Sarah E., et al.
Publicado: (2017)

Nivolumab (PD-1 Inhibitor) Induced Exacerbation of Psoriasis
por: George, Anju, et al.
Publicado: (2020)

The efficacy of treating patients with non-metastatic gastric linitis plastica using surgery with chemotherapy and/or radiotherapy
por: Song, Xueru, et al.
Publicado: (2020)

Metastatic Cutaneous Melanoma of the Gallbladder
por: Patel, Dhruvan, et al.
Publicado: (2017)

Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report
por: Noguchi, Go, et al.
Publicado: (2018)

Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis
por: Yang, Yuanquan, et al.
Publicado: (2022)

Residual cancer is a strong predictor of survival in T3 incidental gallbladder cancer
por: You, Chuan, et al.
Publicado: (2022)

Metastatic Merkel cell carcinoma response to nivolumab
por: Walocko, Frances M., et al.
Publicado: (2016)

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
por: Oro-Ayude, Marcos, et al.
Publicado: (2020)

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
por: Tan, Shuguang, et al.
Publicado: (2017)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Survival benefit of radiotherapy in metastatic esophageal cancer: a population-based study
por: Li, Xiangpan, et al.
Publicado: (2019)

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2023)

Metastatic gallbladder adenosquamous carcinoma to the skin(†)
por: Lupinacci, Renato Micelli, et al.
Publicado: (2014)

Metastatic Melanoma of the Gallbladder in an Asymptomatic Patient
por: Khan, Asad, et al.
Publicado: (2017)

Outcomes of metastatic neuroendocrine carcinoma of the gallbladder
por: Ghosh, Joydeep, et al.
Publicado: (2021)

Successful multimodality treatment of metastatic gallbladder cancer: A case report and review of literature
por: Zhang, Biao, et al.
Publicado: (2022)

Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma
por: Kim, Tae Hyun, et al.
Publicado: (2019)

Nivolumab in Metastatic Non–Small Cell Lung Cancer
por: Deel, Andrea
Publicado: (2016)

Efficacy and safety of nivolumab for metastatic biliary tract cancer
por: Gou, Miaomiao, et al.
Publicado: (2019)

First-line treatment of metastatic melanoma: role of nivolumab
por: Force, Jeremy, et al.
Publicado: (2017)

Erratum to: Metastatic Merkel cell carcinoma response to nivolumab
por: Walocko, Frances M., et al.
Publicado: (2017)

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
por: Diab, Adi, et al.
Publicado: (2021)

Use of Pulsed Low–Dose Rate Radiotherapy in Refractory Malignancies()()
por: Yan, Jing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5f8t9h4n1hkcm1d0fk9oj27ur7